Olaparib
Canadian Journal of Health Technologies · 22.10.2026 · 6 (10)
DOI: 10.51731/cjht.2026.1550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 22.10.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies. This review assesses Olaparib 150 mg oral tablets. Indication under consideration for reimbursement: Olaparib is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor–positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before olaparib treatment is initiated.
Zitieren
APA
CDA-AMC (2026). Olaparib. Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1550
Vancouver
CDA-AMC. Olaparib. Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1550
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Olaparib},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {10},
doi = {10.51731/cjht.2026.1550}
}
EUVIMED